The correlation of age and comorbidity with therapy and survival in cancer patients in North-Brabant and North-Limburg, 1995-2001;Samenhang van leeftijd en comorbiditeit met therapie en overleving bij patiënten met kanker in Noord-Brabant en Noord-Limburg, 1995-2001

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 30, 2005, Pages 1686-1690

  Janssen Heijnen, M L G ^a   Maas, H A A M ^c   Lemmens, V E P P ^a   Houterman, S ^a   Louwman, W J ^a   Verheij, C D G W ^a   Coebergh, J W W ^a,b  

^a The Netherlands   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; COLORECTAL CANCER; COMORBIDITY; HUMAN; LUNG CANCER; NETHERLANDS; OVARY CANCER; PRACTICE GUIDELINE; PROGNOSIS; PROSTATE CANCER;

AGE FACTORS; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; NEOPLASMS; NETHERLANDS; PRACTICE GUIDELINES; REGISTRIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 23844517111     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Visser O, Siesling S, Dijck JAAM van. Incidence of cancer in the Netherlands 1999/2000. Utrecht: Vereniging van Integrale Kankercentra; 2003.
2. Spronsen DJ van, Janssen-Heijnen ML, Lemmens VE, Peters WG, Coebergh JW. Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer 2005;41:1051-7.
3. Maas HA, Kruitwagen RF, Lemmens VE, Goey SH, Janssen-Heijnen ML. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gyn Oncol 2005;97:104-9.
4. Louwman WJ, Janssen-Heijnen ML, Houterman S, Voogd AC, Sangen MJ van der, Nieuwenhuijzen GA, et al. Less extensive treatment and inferior prognosis for breast cancer patients with comorbidity: a population-based study. Eur J Cancer 2005;41:779-85.
5. Lemmens VE, Halteren AH van, Janssen-Heijnen ML, Vreugdenhil G, Repelaer van Driel OJ, Coebergh JW. Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity. Ann Oncol 2005;16:767-72.
6. Lemmens VE, Janssen-Heijnen ML, Verheij CD, Houterman S, Repelaer van Driel OJ, Coebergh JW. Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg 2005;92:615-23.
7. Houterman S, Janssen-Heijnen ML, Verheij CD, Louwman WJ, Vreugdenhil G, Sangen MJ van der, et al. Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients. Br J Cancer 2004;90:2332-7.
8. Janssen-Heijnen ML, Smulders S, Lemmens VE, Smeenk FW, Geffen HJ van, Coebergh JW. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 2004;59:602-7.
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
10. Damhuis RA, Schutte PR. Resection rates and postoperative mortality in 7,899 patients with lung cancer. Eur Respir J 1996;9:7-10.
11. Finlayson EV, Birkmeyer JD. Operative mortality with elective surgery in older adults. Eff Clin Pract 2001;4:172-7.
12. Spronsen DJ van, Janssen-Heijnen ML, Breed WP, Coebergh JW. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol 1999;78:315-9.
13. Forman WB. The role of chemotherapy and adjuvant therapy in the management of colorectal cancer. Cancer 1994;74(7 Suppl):2151-3.
14. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75:11-7.
15. Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Eur J Cancer 1998;34:1871-5.
16. Ayanian JZ, Zaslavsky AM, Fuchs CS, Guadagnoli E, Creech CM, Cress RD, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol 2003;21:1293-300.
17. Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Vercelli M, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002;20:494-502.
18. Rijke JM de, Scheuten LJ, Schouten HC, Jager JJ, Koppejan AG, Brandt PA van den. Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, the Netherlands. Ann Oncol 1996;7:677-85.
19. Post PN, Hansen BE, Kil PJ, Janssen-Heijnen ML, Coebergh JW. The independent prognostic value of comorbidity among men aged < 75 years with localized prostate cancer: a population-based study. BJU Int 2001;87:821-6.
20. Read WL, Tierney RM, Page NC, Costas I, Gorindan R, Spitznagel EL, et al. Differential prognostic impact of comorbidity. J Clin Oncol 2004;22:3099-103.